Relay Therapeutics (RLAY) EBT Margin (2021 - 2026)
Relay Therapeutics (RLAY) posted quarterly EBT Margin of 2637.57% for Q1 2026, down 162224.0% year-over-year from N/an in Q1 2025, and down 426.24% quarter-over-quarter from 501.21% in Q4 2025.
Powered by 
Analysis
Relay Therapeutics (RLAY) EBT Margin (2021 - 2026) Analysis & Trends
Relay Therapeutics (RLAY) has reported EBT Margin for 6 consecutive years, with 2637.57% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT Margin fell 162224.0% year-over-year to 2637.57%; the TTM figure through Mar 2026 stood at 2457.76% (up 724125.0% YoY), while the FY2025 annual figure was 4924.91%, up 276622.0% from the prior year.
- EBT Margin fell to 2637.57% in Q1 2026 per RLAY's latest filing, from 501.21% in the prior quarter.
- Across five years, EBT Margin topped out at 10791300.0% in Q4 2023 and bottomed at 94462.18% in Q2 2023.
- Historically, EBT Margin has averaged 810557.76% across 5 years, with a median of 10927.62% in 2025.
- On a YoY basis, EBT Margin climbed as much as 1082096719 bps in 2023 and fell as far as 6914575 bps in 2023.
- Relay Therapeutics' EBT Margin stood at 29667.19% in 2022, then soared by 36475 bps to 10791300.0% in 2023, then tumbled by 100 bps to 826.5% in 2024, then surged by 39 bps to 501.21% in 2025, then plunged by 426 bps to 2637.57% in 2026.
- Business Quant data shows RLAY's EBT Margin at 2637.57% in Q1 2026, 501.21% in Q4 2025, and 10927.62% in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 12.09% |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -2.67% |
| 10 | Relay Therapeutics | 3.86 Bn | 3.86 Bn | - | -23,916.86% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -23,916.86% |
| Mar 31, 2026 | -2,443.03% |
| Dec 31, 2025 | -784.57% |
| Jun 30, 2025 | -10,301.62% |
| Mar 31, 2025 | -1,003.58% |
| Mar 31, 2024 | -813.55% |
| Dec 31, 2023 | 8,349,600.00% |
| Sep 30, 2023 | -260.82% |
| Jun 30, 2023 | -82,765.55% |
| Mar 31, 2023 | -41,698.67% |
| Dec 31, 2022 | -27,621.34% |
| Sep 30, 2022 | -24,470.64% |
| Jun 30, 2022 | -22,054.52% |
| Mar 31, 2022 | -16,914.56% |
| Dec 31, 2021 | -12,246.56% |
| Sep 30, 2021 | -9,134.08% |
| Jun 30, 2021 | -22,914.69% |
| Mar 31, 2021 | -4,431.09% |